Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 15, 2004; 10(14): 2029-2033
Published online Jul 15, 2004. doi: 10.3748/wjg.v10.i14.2029
Prokaryotic expression and renaturation of engineering chimeric Fab antibody against human hepatoma
Jin-Liang Xing, Xiang-Min Yang, Xi-Ying Yao, Fei Song, Zhi-Nan Chen
Jin-Liang Xing, Xiang-Min Yang, Xi-Ying Yao, Fei Song, Zhi-Nan Chen, Cell Engineering Research Center, Faculty of Preclinical Medicine, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Author contributions: All authors contributed equally to the work.
Supported by the National High Technology Research and Development Program of China (863 Program), No. 2001AA215101 and the National Natural Science Foundation of China, No. 3020330
Correspondence to: Professor Zhi-Nan Chen, Cell Engineering Research Center, Faculty of Preclinical Medicine, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China. chcerc2@fmmu.edu.cn
Telephone: +86-29-3374545 Fax: +86-29-3293906
Received: November 13, 2003
Revised: December 15, 2003
Accepted: January 15, 2004
Published online: July 15, 2004
Abstract

AIM: To express chimeric Fd (cFd) and chimeric light chain (cL) in E. coli respectively and refold them into chimeric Fab (cFab) antibody.

METHODS: cFd and cL genes were respectively inserted into the prokaryotic expression vector pET32a to construct recombinant vectors pET32a/cFd and pET32a/cL. Then, the competent E. coli cells were transformed by the recombinant vectors and induced by IPTG. Moreover, a large quantity of cFd and cL expression products were prepared and mixed with equal molar to refold into cFab by gradient dialysis. The refolded products were identified and analyzed by sodium SDS-PAGE, Western blotting, ELISA and HPLC.

RESULTS: High efficient prokaryotic expressions of both cFd and cL in the form of non-fusion protein were obtained with the expression levels of 28.3% and 32.3% of total bacteria proteins, respectively. Their relative molecular masses were all 24 ku or so, and both of them mainly existed in the form of inclusion bodies. In addition, cFd and cL were successfully refolded into cFab by gradient dialysis, with about 59.45% of recovery when the starting total protein concentration was 100 μg/mL. The renatured cFab could specifically bind to related antigen with high affinity.

CONCLUSION: The cFab antibody against human hepatoma was highly and efficiently expressed and refolded, which laid a solid foundation for studying its application in the treatment of hepatoma.

Keywords: $[Keywords]